Acelyrin — Merger or Acquisition (March 2025)
35 slides from Acelyrin's merger presentation, Mar 11, 2025
Slide 1: Transform Therapies. Reimagine Lives. March 2025 Corporate Presentation
Transform Therapies. Reimagine Lives. March 2025 Corporate Presentation
Slide 2: Forward-Looking Statements
2 © Alumis Forward - Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harb or” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates a nd e
Slide 3: Creating Well Capitalized Company with Multiple Upcoming Development Milestones
1. Preliminary, unaudited and subject to change © Alumis 3 Creating Well Capitalized Company with Multiple Upcoming Expected Development Milestones and Extended Runway into 2027 〉 Creates a late - stage clinical biopharma company dedicated to innovating, developing and commercializing transformative
Slide 4: Late-Stage Pipeline with Multiple Near-Term Catalysts
Late - Stage Pipeline with Multiple Near - Term Catalysts 4 © Alumis 〉 Post transaction close, we expect to evaluate lonigutamab’s promising potential differentiation profile in TED with approximately $25 - 50M of committed capital and the combined expertise of Alumis and the lonigutamab team ANTICI
Slide 5: Recent Achievements and Anticipated Near-Term Milestones
Recent Achievements and Anticipated Multiple Near - Term Milestones 2024 2025 2026 MAR APR JUL 3Q YE ESK - 001 – Present Phase 2 STRIDE and OLE Data at AAD A - 005 – Phase 1 Initiation ESK - 001 – Initiate Phase 3 in PsO ESK - 001 – PsO OLE Data Update A - 005 – Phase 1 Data 1Q 2026 2026 ESK - 001 –
Slide 6: Alumis + ACELYRIN: A Well Characterized Late-Stage Portfolio
6 Alumis + ACELYRIN: A Well Characterized Late - Stage Portfolio with Significant Opportunity Genomic, proteomic and clinical insights validate and drive our Research and Development strategy and increase the probability of technical success (PTS) of our programs Experienced team with strong track r
Slide 7: Extensive Genetic Insights Inform TYK2 Indications
© Alumis 7 Extensive Genetic Insights Inform TYK2 Indications 〉 TYK2 P1104A Loss - of - kinase - function variant stands out in the human genome, conferring powerful protection from broad array of immune - mediated diseases 〉 Out - sized protection conferred by carriers of two P1104A variants (homoz
Slide 8: Maximal Target Inhibition Led to ~20% Increase in Clinical Response
© Alumis 8 Maximal Target Inhibition Led to 15 - 20% Increase in Clinical Response (PASI) Maximal Target Inhibition Maintained Across 24 - hour Dosing Period ( Phase 1 multidose trough PK) Clinical Outcomes at 28 Weeks (OLE Phase 2, PASI as observed) 1 10 100 1000 0 2 4 6 8 10 12 14 ESK - 001 Mean T
Slide 9: ESK-001 and A-005: A Highly Differentiated TYK2i Portfolio
9 ESK - 001 and A - 005: A Highly Differentiated TYK2i Portfolio Phase 3 dose fully inhibits TYK2 by every measure in skin and blood* 〉 Maximal Target Inhibition Long term PASI and sPGA response rates competitive with high efficacy biologics 〉 High Response Oral No major safety signals to date with
Slide 10: TYK2 Class Validation with Substantial Market Potential
TYK2 Class has Extensive Validation with Substantial Market Potential Across Immune - Mediated Diseases Ongoing trials: includes Alumis and other company clinical trials; Publicly disclosed indications for TYK2, Market size estimates for 2030 worldwide Biologic Rationale Genetic Evidence Ongoing Tri
Slide 11: ACELYRIN's Lonigutamab: Next-Generation Subcutaneous Anti-IGF-1R Therapy
ACELYRIN’s Lonigutamab A Next - Generation Subcutaneous Anti - IGF - 1R Therapy With Best - in - Class Potential in TED 11 Lonigutamab Development Plan 〉 Capital Investment: Initial commitment of approximately $25 - $50M to evaluate potential differentiation in TED. Investment has been included in p
Slide 12: ESK-001: TYK2i Achieving Maximal Target Inhibition
ESK - 001: TYK2i Achieving Maximal Target Inhibition
Slide 13: Psoriasis: Large Market with Significant Unmet Need for High Efficacy Oral
ESK - 001 is a next - generation TYK2i with differentiated profile for oral treatment in psoriasis Psoriasis: Large Market with Significant Unmet Need for High Efficacy Oral 1. National Psoriasis Foundation. ~16M patients worldwide with moderate - to - severe disease. 2. 2030 estimates from GlobalDa
Slide 14: 92% of Diagnosed Psoriasis Patients Are Not Treated with a Biologic
1 National Psoriasis Foundation 2 IQVIA Analysis, Stable and eligible newly diagnosed patients from April 2021 – March 2022 utilized for longitudinal analysis; all patients have at least 24M of look forward post - Dx * Last data March 2024; product and market dynamics since March 2024 not reflected
Slide 15: STRIDE Met Primary and Secondary Endpoints at Week 12
*p<0.05; **p< 0.005; ***p<0.001 . P - value is comparing proportion in each active arm vs placebo using the Cochran - Mantel - Haensze l test adjusted for stratification factors (prior use of biologics and geographic region (North American vs. ROW)). © Alumis 15 STRIDE Met Primary and Secondary Endp
Slide 16: STRIDE: ESK-001 Well Tolerated at All Dose Levels
Overall (N=227) 40 mg BID (N=39) 40 mg QD (N=39) 20 mg BID (N=39) 20 mg QD (N=36) 10 mg QD (N=36) Placebo (N=38) 110 (48.5) 25 (64.1) 19 ( 48.7) 18 (46.2) 14 (38.9) 19 (52.8) 15 (39.5) Subjects with ≥1 TEAE 5 (2.2) 0 1 (2.6) 3 (7.7) 0 1 (2.8) 0 Subjects with ≥1 SAE 0 0 0 0 0 0 0 Subjects with treatm
Slide 17: Safety Profile of ESK-001 at Week 52
17 Safety Profile of ESK - 001 at Week 52: No Significant Safety Findings Throughout 52 Weeks Overall (N=164) ESK - 001 40 mg BID* (N=147) ESK - 001 40 mg QD (N=82) EAIR n (%) EAIR n (%) EAIR n (%) 108.18 108 (66) 102.33 73 (50) 122.76 50 (61) Subjects with ≥ 1 TEAE 3.29 6 (4) 3.39 4 (3) 3.10 2 (2)
Slide 18: OLE BID: Significant Increases in PASI Responses with Continued Exposure
OLE BID: Significant Increases in PASI Responses with Continued Exposure with Progressive Achievements in PASI 100 Patient Achieving PASI - 75 (AO) (%) Patient Achieving PASI - 90 (AO) (%) Patient Achieving PASI - 100 (AO) (%) 18 OLE Treatment: ESK - 001 40 mg BID 66 72 71 72 74 82 82 82 As Observed
Slide 19: OLE BID: Consistent Results Supporting Robustness of Methodology
19 Patient Achieving PASI - 75 ( mNRI ) (%) Patient Achieving PASI - 90 ( mNRI ) (%) Patient Achieving PASI - 100 ( mNRI ) (%) Patient Achieving PASI - 75 (AO) (%) Patient Achieving PASI - 90 (AO) (%) Patient Achieving PASI - 100 (AO) (%) OLE Treatment: ESK - 001 40 mg BID Open Label Extension 40 mg
Slide 20: OLE: Sustained and Increasing sPGA Responses
OLE Treatment: ESK - 001 40 mg BID ( mITT Analysis Set) Open Label Extension 40 mg BID Washout STRIDE 20 mg BID 40 mg QD 40 mg BID Placebo Patient with Response (%) 100 80 60 40 20 0 20 OLE: Sustained and Increasing sPGA Responses with Continued Exposure Patient Achieving sPGA 0 (A0) (%) Patient Ach
Slide 21: Patient-reported Outcomes Throughout Week 52
Based on the modified intention - to - treat analysis population. mNRI analysis: if patient discontinued due to AE or inadequate response, then imputed as a non - responder; if discontinued for other reasons, then imputed using LOCF (i.e., last observation carried forward). DLQI, Dermatology Life Qu
Slide 22: PASI-75 Over Time for OLE 40 mg BID Cohort by STRIDE Dose
NUMBER OF SUBJECTS Washout STRIDE 20 mg BID 40 mg QD 40 mg BID Placebo Proportion with PASI - 75 Response (%) 100 80 60 40 20 0 Baseline P W12 D1 W2 W4 VISIT > Open Label Extension 40 mg BID OLE Treatment: ESK - 001 40 mg BID *Data as of September 6, 2024 W8 W12 W16 W28 W40 W52 PASI - 75 Over Time f
Slide 23: Psoriasis: Current Treatment Landscape
© Alumis 23 Psoriasis: Current Treatment Landscape Maximal response is Achieved at Week 24 and Beyond Percent of Patients Achieving PASI - 75 Time (Weeks) Skyrizi IL - 23 Cosentyx IL - 17 Stelara IL - 12/23 JNJ2113 IL - 23 oral Sotyktu TYK2 oral Otezla PDE4 oral PASI 75 Outcomes for Recent Psoriasis
Slide 24: Psoriasis: ESK-001 Phase 3 ONWARD Program
24 Psoriasis: ESK - 001 Phase 3 ONWARD Program Three Studies: Two parallel Phase 3 studies and a long - term extension (LTE) study ESK - 001, 40mg BID (N=420) Treatment Period Maintenance Placebo (N= 210 ) Wk 16 : Rollover to ESK - 001 Apremilast, 30mg BID (N=210) ESK - 001 (Open Label) ONWARD3 (Lon
Slide 25: SLE: Ongoing Phase 2b LUMUS Program
SLE: Ongoing Phase 2b Program (LUMUS) is Designed for Speed to Market and Probability of Clinical Success 25 〉 High unmet need for safe and effective treatment in SLE – No oral targeted treatments available at this time – Opportunity to expand into lupus nephritis, cutaneous lupus 〉 Multiple points
Slide 26: LUMUS Trial Incorporates Key Learnings from Past SLE Trials
© Alumis 26 LUMUS Trial Incorporates Key Learnings from Past SLE Trials 〉 High placebo response rates responsible for failed SLE trials driven by: – Insufficient disease activity – Excessive concomitant medications – Incorrect/inconsistent use of composite outcome measures – Trial design and/or cond
Slide 27: A-005: First-in-Class, CNS-Penetrant Allosteric TYK2 Inhibitor
A - 005: First - in - Class, CNS - Penetrant Allosteric TYK2 Inhibitor
Slide 28: A-005: A First-in-Class CNS-Penetrant Allosteric TYK2 Inhibitor
28 A - 005: A First - in - Class CNS - Penetrant Allosteric TYK2 Inhibitor A Foundational Oral Immunology Drug Candidate for Neuroinflammation Achieves CSF:Plasma (free drug) ratio of approximately 1:1 〉 Fully CNS - Penetrant Achieves IC90 coverage within the CNS and peripherally over the dosing per
Slide 29: A-005 Preclinical EAE Model Efficacy
Once daily oral dosing initiated 1 day prior to EAE induction; Mann - Whitney U test vs vehicle, p<0.05 for 1 mg/kg (day 20 - 28), 3 mg/kg (day 20 - 28), 10 mg/kg (day 14 - 28), 30 mg/kg (day 14 - 28) (Gorman, J. A., Hundhausen , C., Kinsman, M., Arkatkar , T., Allenspach , E. J., Clough, C., West,
Slide 30: A-005 Dose Dependent Plasma Exposure with Sustained PD Effect in Phase 1
© Alumis 30 A - 005 Demonstrated Dose Dependent Plasma Exposure with Sustained and Maximal PD Effect in Phase 1 〉 A - 005 plasma exposure ( C max , AUC) increased proportional to dose, in the range of 1 to 240 mg QD dose 〉 Several higher A - 005 doses sustained in vitro pSTAT IC 90 coverage over 24h
Slide 31: A-005 Demonstrated Ability to Cross Blood-Brain Barrier
CSF free ≥ Plasma free exposure for all timepoints from 1h postdose © Alumis 31 A - 005 Demonstrated Ability to Cross Blood - Brain Barrier with High Levels of Exposure in Cerebral Spinal Fluid (CSF) in Phase 1 PK Summary: CSF Cohort (120 mg QD) C 9h (ng/mL) C max (ng/mL) T max (h) 75 (16) 327 (0.6)
Slide 32: Clinical Development Strategy for A-005
Clinical Development Strategy for A - 005 32 Goal : Establish Clinical Proof - of - Concept in First Neuroinflammatory Indication by 2026 © Alumis Positive Phase 1 Clinical Trial Completed 〉 Established CSF exposure and ability to maximally inhibit TYK2 across broad range of Ph2 doses 〉 Favorable sa
Slide 33: Summary
Summary % alumis
Slide 34: ACELYRIN Transaction Highlights
1. On a fully diluted basis 2. Preliminary, unaudited and subject to change © Alumis 34 ACELYRIN Transaction Highlights 〉 All stock merger 〉 ACELYRIN stockholders to receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned Consideration 〉 Alumis stockholders to own
Slide 35: Thank You!
Thank You! & alumis 35